Chronic back pain tech gets $20m boost
This article was originally published in Clinica
Relievant Medsystems is to expand clinical trials of its Intracept minimally-invasive treatment for chronic low back pain later this year, after raising $20m in new capital. The funds came from new investors Morgenthaler Ventures – which led the financing – and Emergent Medical Partners, as well as Relievant's existing shareholders Canaan Partners and ONSET Ventures.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.